EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease

Charisse N Winston, Oliver Langford, Natalie Levin, Rema Raman, Kevin Yarasheski, Tim West, Sara Abdel-Latif, Michael Donohue, Akinori Nakamura, Kenji Toba, Colin L Masters, James Doecke und 3 weitere

Journal of Alzheimer's Disease · 2023

DOI: 10.3233/jad-221118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Charisse N Winston und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Participant eligibility for the A4 Study was determined by amyloid PET imaging. Given the disadvantages of amyloid PET imaging in accessibility and cost, blood-based biomarkers may serve as a sufficient biomarker and more cost-effective screening tool for patient enrollment into preclinical AD trials.

Objective

To determine if a blood-based screening test can adequately identify amyloid burden in participants screened into a preclinical AD trial.

Methods

In this cross-sectional study, 224 participants from the A4 Study received an amyloid PET scan (18Florbetapir) within 90 days of blood sample collection. Blood samples from all study participants were processed within 2 h after phlebotomy. Plasma amyloid measures were quantified by Shimazdu and C2 N Diagnostics using mass spectrometry-based platforms. A corresponding subset of blood samples (n = 100) was processed within 24 h after phlebotomy and analyzed by C2 N.

Results

Plasma Aβ42/Aβ40 demonstrated the highest association for Aβ accumulation in the brain with an AUC 0.76 (95%CI = 0.69, 0.82) at C2 N and 0.80 (95%CI = 0.75, 0.86) at Shimadzu. Blood samples processed to plasma within 2 h after phlebotomy provided a better prediction of amyloid PET status than blood samples processed within 24 h (AUC 0.80 versus 0.64; p < 0.001). Age, sex, and APOE ɛ4 carrier status did not the diagnostic performance of plasma Aβ42/Aβ40 to predict amyloid PET positivity in A4 Study participants.

Conclusion

Plasma Aβ42/Aβ40 may serve as a potential biomarker for predicting elevated amyloid in the brain. Utilizing blood testing over PET imaging may improve screening efficiency into clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloid beta-PeptidesCross-Sectional StudiesAmyloidAmyloidogenic ProteinsBiomarkersPositron-Emission TomographyPeptide Fragments

Stichwörter der Autor:innen

A4Alzheimer’s diseasePETamyloid-βbiomarkersclinical trialmass spectrometry

Substanzen

Amyloid beta-PeptidesAmyloidAmyloidogenic ProteinsBiomarkersPeptide Fragments

Autor:innen und Institutionen

  • Department of Neurosciences, University of California San Diego, La Jolla, CA, USA.
  • Alzheimer's Therapeutic Research Institute, Keck School of Medicine University of Southern California, San Diego, CA, USA.
  • C2N Diagnostics, St. Louis, MO, USA.
  • Department of Biomarker Research, National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
  • National Center for Geriatrics and Gerontology, Obu, Aichi, Japan.
  • Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

Förderung

  • NIA NIH HHS

Zitieren

APA

Winston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K., West, T., Abdel-Latif, S., Donohue, M., Nakamura, A., Toba, K., Masters, C. L., Doecke, J., Sperling, R. A., Aisen, P. S., & Rissman, R. A. (2023). Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-221118

Vancouver

Winston CN, Langford O, Levin N, Raman R, Yarasheski K, West T, et al. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-221118

BibTeX
@article{Winston2023,
  author = {Winston, Charisse N and Langford, Oliver and Levin, Natalie and Raman, Rema and Yarasheski, Kevin and West, Tim and Abdel-Latif, Sara and Donohue, Michael and Nakamura, Akinori and Toba, Kenji and Masters, Colin L and Doecke, James and Sperling, Reisa A and Aisen, Paul S and Rissman, Robert A},
  title = {Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease},
  journal = {Journal of Alzheimer's Disease},
  year = {2023},
  doi = {10.3233/jad-221118}
}
Kostenlos starten →